In this study, a post-neoadjuvant ADT PSA nadir of 3⁄4 1 ng/ml predicted a higher rate of biochemical control and a higher overall survival in men with unfavorable prostate cancer treated with EBRT (25). This evidence concerns the gene KLK3 and prostate cancer.